<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30150398</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>15</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1091-6490</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>115</Volume>                    <Issue>37</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>09</Month>                        <Day>11</Day>                    </PubDate>                </JournalIssue>                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>            </Journal>            <ArticleTitle>Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.</ArticleTitle>            <Pagination>                <MedlinePgn>E8717-E8726</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1807105115</ELocationID>            <Abstract>                <AbstractText>Blood-brain/blood-tumor barriers (BBB and BTB) and interstitial transport may constitute major obstacles to the transport of therapeutics in brain tumors. In this study, we examined the impact of focused ultrasound (FUS) in combination with microbubbles on the transport of two relevant chemotherapy-based anticancer agents in breast cancer brain metastases at cellular resolution: doxorubicin, a nontargeted chemotherapeutic, and ado-trastuzumab emtansine (T-DM1), an antibody-drug conjugate. Using an orthotopic xenograft model of HER2-positive breast cancer brain metastasis and quantitative microscopy, we demonstrate significant increases in the extravasation of both agents (sevenfold and twofold for doxorubicin and T-DM1, respectively), and we provide evidence of increased drug penetration (&gt;100 vs. &lt;20 µm and 42 ± 7 vs. 12 ± 4 µm for doxorubicin and T-DM1, respectively) after the application of FUS compared with control (non-FUS). Integration of experimental data with physiologically based pharmacokinetic (PBPK) modeling of drug transport reveals that FUS in combination with microbubbles alleviates vascular barriers and enhances interstitial convective transport via an increase in hydraulic conductivity. Experimental data demonstrate that FUS in combination with microbubbles enhances significantly the endothelial cell uptake of the small chemotherapeutic agent. Quantification with PBPK modeling reveals an increase in transmembrane transport by more than two orders of magnitude. PBPK modeling indicates a selective increase in transvascular transport of doxorubicin through small vessel wall pores with a narrow range of sizes (diameter, 10-50 nm). Our work provides a quantitative framework for the optimization of FUS-drug combinations to maximize intratumoral drug delivery and facilitate the development of strategies to treat brain metastases.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Arvanitis</LastName>                    <ForeName>Costas D</ForeName>                    <Initials>CD</Initials>                    <AffiliationInfo>                        <Affiliation>School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332; costas.arvanitis@gatech.edu jain@steele.mgh.harvard.edu.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Askoxylakis</LastName>                    <ForeName>Vasileios</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guo</LastName>                    <ForeName>Yutong</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Datta</LastName>                    <ForeName>Meenal</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Chemical and Biological Engineering, Tufts University, Medford, MA 02155.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kloepper</LastName>                    <ForeName>Jonas</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferraro</LastName>                    <ForeName>Gino B</ForeName>                    <Initials>GB</Initials>                    <AffiliationInfo>                        <Affiliation>Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bernabeu</LastName>                    <ForeName>Miguel O</ForeName>                    <Initials>MO</Initials>                    <AffiliationInfo>                        <Affiliation>Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh EH16 4UX, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fukumura</LastName>                    <ForeName>Dai</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>McDannold</LastName>                    <ForeName>Nathan</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jain</LastName>                    <ForeName>Rakesh K</ForeName>                    <Initials>RK</Initials>                    <AffiliationInfo>                        <Affiliation>Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; costas.arvanitis@gatech.edu jain@steele.mgh.harvard.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P01 CA174645</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>F31 HL126449</GrantID>                    <Acronym>HL</Acronym>                    <Agency>NHLBI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>U01 CA224348</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 CA129371</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R35 CA197743</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>P01 CA080124</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 CA208205</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R00 EB016971</GrantID>                    <Acronym>EB</Acronym>                    <Agency>NIBIB NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>P50 CA165962</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>            <NlmUniqueID>7505876</NlmUniqueID>            <ISSNLinking>0027-8424</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>14083FR882</RegistryNumber>                <NameOfSubstance UI="D008453">Maytansine</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>80168379AG</RegistryNumber>                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P188ANX8CK</RegistryNumber>                <NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>SE2KH7T06F</RegistryNumber>                <NameOfSubstance UI="C550911">ado-trastuzumab emtansine</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosurg Focus. 2015 Mar;38(3):E10</RefSource>                <PMID Version="1">25727219</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Nov 8;367(19):1783-91</RefSource>                <PMID Version="1">23020162</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cereb Blood Flow Metab. 2012 Oct;32(10):1948-58</RefSource>                <PMID Version="1">22805875</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Trends Cancer. 2018 Apr;4(4):292-319</RefSource>                <PMID Version="1">29606314</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Microvasc Res. 1996 May;51(3):327-46</RefSource>                <PMID Version="1">8992232</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Transl Med. 2016 Jun 15;8(343):343re2</RefSource>                <PMID Version="1">27306666</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neuroimage. 2005 Jan 1;24(1):12-20</RefSource>                <PMID Version="1">15588592</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100</RefSource>                <PMID Version="1">9588554</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ultrasound Med Biol. 2006 Sep;32(9):1399-409</RefSource>                <PMID Version="1">16965980</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neoplasia. 2000 Jul-Aug;2(4):325-38</RefSource>                <PMID Version="1">11005567</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Microvasc Res. 1996 Jul;52(1):27-46</RefSource>                <PMID Version="1">8812751</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2017 Jan 15;77(2):238-246</RefSource>                <PMID Version="1">27815391</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Ther. 2009 Oct;8(10):2861-71</RefSource>                <PMID Version="1">19825804</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Syst Biol. 2015 Jan;64(1):e1-25</RefSource>                <PMID Version="1">25293804</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2016 Sep 15;6:33264</RefSource>                <PMID Version="1">27630037</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ACS Nano. 2014 Apr 22;8(4):3678-89</RefSource>                <PMID Version="1">24673594</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Jun 2;7(1):2733</RefSource>                <PMID Version="1">28578390</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18632-7</RefSource>                <PMID Version="1">24167277</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Nanotechnol. 2012 Apr 08;7(6):383-8</RefSource>                <PMID Version="1">22484912</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Neurosci. 2006 Jan;7(1):41-53</RefSource>                <PMID Version="1">16371949</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2017 Nov;17(11):659-675</RefSource>                <PMID Version="1">29026204</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Microvasc Res. 1989 Jan;37(1):77-104</RefSource>                <PMID Version="1">2646512</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nature. 2015 Jul 16;523(7560):337-41</RefSource>                <PMID Version="1">26030524</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pharm Res. 2012 Mar;29(3):770-81</RefSource>                <PMID Version="1">22011930</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Drug Deliv Rev. 2014 Jun;72:94-109</RefSource>                <PMID Version="1">24462453</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Adv. 2018 Jan 10;4(1):e1701676</RefSource>                <PMID Version="1">29349296</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2008 Nov 15;68(22):9280-90</RefSource>                <PMID Version="1">19010901</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2017 Dec;17(12):738-750</RefSource>                <PMID Version="1">29123246</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2016 Apr 11;29(4):508-522</RefSource>                <PMID Version="1">27050100</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Drug Deliv Rev. 2017 Sep 15;119:159-174</RefSource>                <PMID Version="1">28648712</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Dec 15;22(24):6078-6087</RefSource>                <PMID Version="1">27521448</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Radiology. 2001 Sep;220(3):640-6</RefSource>                <PMID Version="1">11526261</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2002 Apr;2(4):266-76</RefSource>                <PMID Version="1">12001988</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Clin Oncol. 2010 Nov;7(11):653-64</RefSource>                <PMID Version="1">20838415</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2012;7(9):e45783</RefSource>                <PMID Version="1">23029240</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 Feb 1;30(4):419-25</RefSource>                <PMID Version="1">22203767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Microvasc Res. 1991 Jan;41(1):5-23</RefSource>                <PMID Version="1">2051954</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1987 Jun 15;47(12):3039-51</RefSource>                <PMID Version="1">3555767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drug Des Devel Ther. 2015 Jun 29;9:3341-8</RefSource>                <PMID Version="1">26170620</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2016 Nov 1;22(21):5287-5299</RefSource>                <PMID Version="1">27245829</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2007 Mar 15;67(6):2729-35</RefSource>                <PMID Version="1">17363594</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Rep. 2017 Jan 06;7:39955</RefSource>                <PMID Version="1">28059117</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2010 Jun 1;70(11):4443-52</RefSource>                <PMID Version="1">20460537</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Phys Med Biol. 2014 Oct 21;59(20):5987-6004</RefSource>                <PMID Version="1">25230100</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2014 Nov 10;26(5):605-22</RefSource>                <PMID Version="1">25517747</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Protoc. 2018 May;13(5):1091-1105</RefSource>                <PMID Version="1">29674756</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Biomed Eng. 2016;1:null</RefSource>                <PMID Version="1">28966873</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2018 Apr 15;24(8):1795-1804</RefSource>                <PMID Version="1">29437794</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Sci Transl Med. 2017 May 24;9(391):</RefSource>                <PMID Version="1">28539475</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Control Release. 2016 Sep 28;238:281-288</RefSource>                <PMID Version="1">27496633</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pharm Sci. 1983 Oct;72(10):1103-27</RefSource>                <PMID Version="1">6358460</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Drug Deliv Rev. 2008 Jun 30;60(10):1193-208</RefSource>                <PMID Version="1">18474406</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Brain Res. 2016 Sep 1;1646:543-550</RefSource>                <PMID Version="1">27369449</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Commun. 2013;4:1504</RefSource>                <PMID Version="1">23422672</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2013 Mar 21;32(12):1539-48</RefSource>                <PMID Version="1">22614016</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2012 Mar 15;72(6):1485-93</RefSource>                <PMID Version="1">22282664</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Theor Biol Med Model. 2009 Aug 09;6:16</RefSource>                <PMID Version="1">19664243</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Mater. 2013 Nov;12(11):958-62</RefSource>                <PMID Version="1">24150413</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Cell. 2015 Feb 9;27(2):163-75</RefSource>                <PMID Version="1">25670078</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Drug Discov. 2016 Apr;15(4):275-92</RefSource>                <PMID Version="1">26794270</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cereb Blood Flow Metab. 2011 Sep;31(9):1852-62</RefSource>                <PMID Version="1">21505473</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2015 Nov 07;108(2):</RefSource>                <PMID Version="1">26547932</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2010 Dec 1;16(23):5664-78</RefSource>                <PMID Version="1">20829328</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2015 Oct 20;33(30):3475-84</RefSource>                <PMID Version="1">26282648</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2008 Sep;19(9):1530-9</RefSource>                <PMID Version="1">18480068</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1992 Oct 15;52(20):5838-44</RefSource>                <PMID Version="1">1394212</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2015 Jul;16(7):e362-9</RefSource>                <PMID Version="1">26149888</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2011 Oct;11(5):275-82</RefSource>                <PMID Version="1">21729661</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2012 Jul 15;72(14):3652-63</RefSource>                <PMID Version="1">22552291</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Control Release. 2012 Nov 10;163(3):277-84</RefSource>                <PMID Version="1">23000189</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3119-27</RefSource>                <PMID Version="1">23071298</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008453" MajorTopicYN="N">Maytansine</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045423" MajorTopicYN="N">Microbubbles</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068878" MajorTopicYN="N">Trastuzumab</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName>                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">blood–brain/blood–tumor barrier</Keyword>            <Keyword MajorTopicYN="Y">brain tumor</Keyword>            <Keyword MajorTopicYN="Y">drug transport</Keyword>            <Keyword MajorTopicYN="Y">focused ultrasound</Keyword>            <Keyword MajorTopicYN="Y">pharmacokinetics</Keyword>        </KeywordList>        <CoiStatement>Conflict of interest statement: R.K.J. received an honorarium from Amgen and consultant fees from Merck, Ophthotech, Pfizer, SPARC, SynDevRx, and XTuit; owns equity in Enlight, Ophthotech, SynDevRx, and XTuit; served on the Board of Directors of XTuit; and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund, and Tekla World Healthcare Fund. Neither any reagent nor any funding from these organizations was used in this study.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pmc-release">                <Year>2019</Year>                <Month>03</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>16</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>29</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30150398</ArticleId>            <ArticleId IdType="pii">1807105115</ArticleId>            <ArticleId IdType="doi">10.1073/pnas.1807105115</ArticleId>            <ArticleId IdType="pmc">PMC6140479</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>